Scripps Research Scientists Identify Genetic Cause for
Type of Deafness
September 2009
Editor: Here's more good news for folks with hearing loss; another
genetic cause has been discovered, this one by researchers at The Scripps
Research Institute. Here's their press release.
~~~~~~~~~~~~~~~~~
Discovery Could Lead to New Therapies for Progressive Hearing Loss
A team led by scientists from The Scripps Research Institute has
discovered a genetic cause of progressive hearing loss. The findings will
help scientists better understand the nature of age-related decline in
hearing and may lead to new therapies to prevent or treat the condition.
The findings were published the September 3, 2009, in an advance,
online issue of the American Journal of Human Genetics, a publication of
Cell Press.
"It is thought that mutations in several hundred genes can lead to
deafness," said team leader Ulrich Mueller, a professor in the Department
of Cell Biology and member of the Skaggs Institute for Chemical Biology at
Scripps Research. "However, for many forms of deafness, we don't know what
effects the genes have. In this new research, we have linked a previously
uncharacterized gene to deafness, first in mice and then in humans."
The team found that the gene responsible for the hearing loss-called
Loxhd1-is necessary for maintaining proper functioning hair cells in the
inner ear. Mutations in Loxhd1 lead to degradation of the hair cells and a
disruption of the process that enables hearing.
Tracking Down a New Gene
In the new study, members of the Mueller lab used a technique called
forward genetics in their quest to better understand the genetic basis of
hearing and hearing loss.
In forward genetics, scientists make mutations at random in germ cells,
screen the resulting models for physical characteristics of interest (in
this case hearing impairment), then amplify these traits through the
breeding of several generations. The gene responsible for the trait is
then identified through positional cloning.
In this case, the scientists were able to generate a new mouse line
with hearing impairment that they called samba and then clone the gene
responsible, Loxhd1, which had never before been associated with deficits
in hearing. When the mice inherited two copies of the mutated gene, they
were profoundly deaf shortly after birth.
The scientists' next task was to determine why.
Normally, "hair cells" or stereocilia in the inner ear respond to fluid
motion or fluid pressure changes caused by sound waves that enter the
outer ear, travel down the ear canal into the middle ear, then strike the
eardrum, which vibrates and moves a set of delicate bones that communicate
with the inner ear. There, the movement of the stereocilia transmits
signals to sensory neurons, sending signals to the brain and eventually
resulting in hearing.
The scientists found that mutations in the Loxhd1 gene did not appear
to affect the initial development of the stereocilia. However, these
mutations did impair the function and maintenance of these essential
structures, eventually leading to their degradation and to hearing loss.
But one essential question remained-was there a parallel gene in humans
that also caused hearing impairment?
To find out, the Mueller lab reached out to Professor Richard J. H.
Smith, the Sterba Hearing Research Professor at Carver College of
Medicine, Iowa State University. Smith had been spearheading an effort to
collect DNA samples from deaf families for years, and had hundreds of
groups of samples in which to search for Loxhd1. Indeed, when the analysis
was completed, the team found that mutations in the Loxhd1 gene were
present in some of these families with hearing loss.
Clues to Age-Related Deafness
This is the third hearing-related gene that the Mueller lab has
discovered, and one he is particularly excited about.
"In humans, the prevailing difficulty is progressive hearing loss," he
said. "As you age, you lose your hearing slowly. Since this mutation can
lead to progressive hearing loss, it provides us with more information on
the genetic underpinnings of this condition and gives us clues as to how
it might be corrected."
Mueller's lab is currently investigating the possibility that a
therapeutic drug could be effective in reversing the molecular problems
that result from the defective gene.
The first authors of the paper, "Mutations in LOXHD1, an evolutionarily
conserved stereociliary protein, disrupt hair cell function in mice and
cause progressive hearing loss in humans," are Nicolas Grillet and Martin
Schwander of Scripps Research.
In addition to Mueller, Smith, Grillet, and Schwander, authors of the
paper include: Michael S. Hildebrand of the University of Iowa City; Anna
Sczaniecka, Anand Kolatkar, and Peter Kuhn of Scripps Research; Janice
Velasco of the Translational Genomics Research Institute; Jennifer A.
Webster, Kimia Kahrizi, and Hossein Najmabadi of the University of Social
Welfare and Rehabilitation, Iran; William J. Kimberling of the Boys Town
National Research Hospital; Dietrich Stephan of the Genome Institute of
the Novartis Research Foundation, Arizona Alzheimer's Consortium and
Banner
Alzheimer's Institute; Melanie Bahlo of The Walter and Eliza Hall
Institute of Medical Research, Australia; and Tim Wiltshire and Lisa M.
Tarantino of the University of North Carolina, Chapel Hill.
The research was supported by the National Institute on Deafness and
Other Communication Disorders of the National Institutes of Health and the
Skaggs Institute for Chemical Biology, as well as a fellowship from the
Bruce Ford and Anne Smith Bundy Foundation, an Australian National Health
and Medical Research Council (NHMRC) Career Development Award, and a NHMRC
Overseas Biomedical Fellowship.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest
independent, non-profit biomedical research organizations, at the
forefront of basic biomedical science that seeks to comprehend the most
fundamental processes of life. Scripps Research is internationally
recognized for its discoveries in immunology, molecular and cellular
biology, chemistry, neurosciences, autoimmune, cardiovascular, and
infectious diseases, and synthetic vaccine development. Established in its
current configuration in 1961, it employs approximately 3,000 scientists,
postdoctoral fellows, scientific and other technicians, doctoral degree
graduate students, and administrative and technical support personnel.
Scripps Research is headquartered in La Jolla, California. It also
includes Scripps Florida, whose researchers focus on basic biomedical
science, drug discovery, and technology development. The Scripps Florida
campus is in Jupiter, Florida.